Literature DB >> 14568857

Delayed drug hypersensitivity reactions.

Werner J Pichler1.   

Abstract

Immune reactions to small molecular compounds, such as drugs, can cause a variety of diseases involving the skin, liver, kidney, and lungs. In many drug hypersensitivity reactions, drug-specific CD4+ and CD8+ T cells recognize drugs through their alphabeta T-cell receptors in an MHC-dependent way. Drugs stimulate T cells if they act as haptens and bind covalently to peptides or if they have structural features that allow them to interact with certain T-cell receptors directly. Immunohistochemical and functional studies of drug-reactive T cells in patients with distinct forms of exanthema reveal that distinct T-cell functions lead to different clinical phenotypes. In maculopapular exanthema, perforin-positive and granzyme B-positive CD4+ T cells kill activated keratinocytes, while a large number of cytotoxic CD8+ T cells in the epidermis is associated with formation of vesicles and bullae. Drug-specific T cells also orchestrate inflammatory skin reactions through the release of various cytokines (for example, interleukin-5, interferon) and chemokines (such as interleukin-8). Activation of T cells with a particular function seems to lead to a specific clinical picture (for example, bullous or pustular exanthema). Taken together, these data allow delayed hypersensitivity reactions (type IV) to be further subclassified into T-cell reactions, which through the release of certain cytokines and chemokines preferentially activate and recruit monocytes (type IVa), eosinophils (type IVb), or neutrophils (type IVd). Moreover, cytotoxic functions by either CD4+ or CD8+ T cells (type IVc) seem to participate in all type IV reactions.

Entities:  

Mesh:

Year:  2003        PMID: 14568857     DOI: 10.7326/0003-4819-139-8-200310210-00012

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  118 in total

Review 1.  Mechanisms of drug toxicity and relevance to pharmaceutical development.

Authors:  F Peter Guengerich
Journal:  Drug Metab Pharmacokinet       Date:  2010-10-22       Impact factor: 3.614

Review 2.  The role of T cells in drug reaction.

Authors:  Andrea Cavani; Ornella De Pità
Journal:  Curr Allergy Asthma Rep       Date:  2006-02       Impact factor: 4.806

Review 3.  Antibiotic Allergy in Pediatrics.

Authors:  Allison Eaddy Norton; Katherine Konvinse; Elizabeth J Phillips; Ana Dioun Broyles
Journal:  Pediatrics       Date:  2018-05       Impact factor: 7.124

4.  Acute generalised exanthematous pustulosis (AGEP) after cefotaxime use.

Authors:  Amel Chaabane; Karim Aouam; Khaled Harrathi; Najib Ben Yahia; Elyes Gassab; Leila Njim; Naceur A Boughattas
Journal:  BMJ Case Rep       Date:  2009-05-25

Review 5.  Delayed drug hypersensitivity: models of T-cell stimulation.

Authors:  Jacqueline Adam; Werner J Pichler; Daniel Yerly
Journal:  Br J Clin Pharmacol       Date:  2011-05       Impact factor: 4.335

Review 6.  General principles of investigating and managing drug allergy.

Authors:  Anthony Frew
Journal:  Br J Clin Pharmacol       Date:  2011-05       Impact factor: 4.335

Review 7.  Noncovalent interactions of drugs with immune receptors may mediate drug-induced hypersensitivity reactions.

Authors:  Basil O Gerber; Werner J Pichler
Journal:  AAPS J       Date:  2006-03-17       Impact factor: 4.009

8.  Clindamycin-induced acute cholestatic hepatitis.

Authors:  Cem Aygun; Orhan Kocaman; Yesim Gurbuz; Omer Senturk; Sadettin Hulagu
Journal:  World J Gastroenterol       Date:  2007-10-28       Impact factor: 5.742

9.  Sulfasalazine-induced hypersensitivity syndrome and hemophagocytic syndrome associated with reactivation of Epstein-Barr virus.

Authors:  Atsushi Komatsuda; Yohsuke Okamoto; Takashi Hatakeyama; Hideki Wakui; Ken-ichi Sawada
Journal:  Clin Rheumatol       Date:  2007-10-19       Impact factor: 2.980

10.  Patch testing in non-immediate drug eruptions.

Authors:  Antonino Romano; Marinella Viola; Francesco Gaeta; Gabriele Rumi; Michela Maggioletti
Journal:  Allergy Asthma Clin Immunol       Date:  2008-06-15       Impact factor: 3.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.